デフォルト表紙
市場調査レポート
商品コード
1536117

起立性低血圧治療薬の世界市場

Orthostatic Hypotension Drugs


出版日
ページ情報
英文 286 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
起立性低血圧治療薬の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

起立性低血圧治療薬の世界市場は2030年までに18億米ドルに達する見込み

2023年に11億米ドルと推定される起立性低血圧治療薬の世界市場は、2030年には18億米ドルに達し、分析期間2023-2030年のCAGRは7.8%で成長すると予測されます。本レポートで分析したセグメントの1つであるミドドリン医薬品は、CAGR 9.1%を記録し、分析期間終了時には9億4,330万米ドルに達すると予測されます。ノルテラ(ドロキシドパ)医薬品セグメントの成長率は、分析期間中CAGR 7.2%と推定されます。

米国市場は2億9,560万米ドル、中国はCAGR12.5%で成長予測

米国の起立性低血圧治療薬市場は2023年に2億9,560万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR12.5%を牽引し、2030年までに4億1,680万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と7.7%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の起立性低血圧治療薬市場- 主要動向と促進要因まとめ

起立性低血圧(姿勢低血圧としても知られる)は、座った状態や横になった状態から立ち上がったときに血圧が著しく低下することを特徴とする病態であり、めまい、ふらつき、あるいは失神などの症状を引き起こします。起立性低血圧は、特に高齢者やパーキンソン病などの神経疾患を持つ人に多くみられます。起立性低血圧の治療は、主に血圧を上昇させ、血流を改善することを目的としています。この病態によく使用される薬剤には、最小の動脈と静脈の受容体を活性化して血管緊張と血圧を上昇させるミドドリンや、ナトリウム貯留を増強して循環系の体液量を増加させるフルドロコルチゾンなどがあります。さらに、塩分摂取量の増加、圧迫ストッキングの着用、身体操作などの非薬理学的戦略が、薬物療法と並行して推奨されることも多いです。

起立性低血圧の治療薬の開発は比較的緩やかで、治療よりも対症療法に重点を置いてきました。しかし、最近、この病態の基礎となる病態生理学的メカニズムの解明が進み、標的薬物療法の可能性が開けてきました。研究者たちは、血圧や血管緊張の調節におけるさまざまな神経伝達物質やホルモン経路の役割を探求しています。その結果、これらの経路をより正確に調節することを目的とした治療法が研究されるようになり、より効果的で持続可能な治療法を提供できる可能性が出てきました。例えば、自律神経系の反応性を高めたり、心拍出量を改善したりする新規薬剤が研究されています。さらに、起立性低血圧に関与する複数の機序に対処する併用療法への関心が高まっており、治療へのより総合的なアプローチが提供されています。

起立性低血圧治療薬市場の成長は、世界人口の高齢化、糖尿病や心臓病の有病率の増加、診断技術の向上による病態の発見率の向上など、いくつかの要因によってもたらされます。生理的な変化や併存疾患のために起立性低血圧の影響を受けやすい高齢者人口の増加に伴い、効果的な治療に対する需要も増加しています。さらに、医療技術や診断の進歩により、起立性低血圧を含むさまざまな形態の血圧調節異常の同定や理解が進み、より的を絞った介入につながるようになっています。消費者の行動もこの市場に影響を及ぼしており、患者は大きな副作用を伴わずに症状を素早く緩和し、生活の質を改善する治療法を求めています。複雑な健康プロファイルを持つ患者の起立性低血圧を管理する必要性から、既存の高血圧治療薬と安全に併用できる新薬の開発も重要な研究分野です。これらの推進力を総合すると、起立性低血圧治療薬の開発への継続的な投資と技術革新が確実なものとなります。

調査対象企業の例(全86件)

  • Alembic Pharmaceuticals, Inc.
  • Avalo Therapeutics, Inc
  • Baxter International, Inc.
  • CuraSen Therapeutics
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Luye Pharma Group
  • Manus Aktteva Biopharma LLP
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Upsher-Smith Laboratories LLC
  • Viatris
  • Zydus Lifesciences Limited

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26640

Global Orthostatic Hypotension Drugs Market to Reach US$1.8 Billion by 2030

The global market for Orthostatic Hypotension Drugs estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Midodrine Drug, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$943.3 Million by the end of the analysis period. Growth in the Northera (Droxidopa) Drug segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$295.6 Million While China is Forecast to Grow at 12.5% CAGR

The Orthostatic Hypotension Drugs market in the U.S. is estimated at US$295.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$416.8 Million by the year 2030 trailing a CAGR of 12.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Orthostatic Hypotension Drugs Market - Key Trends and Drivers Summarized

Orthostatic hypotension, also known as postural hypotension, is a condition characterized by a significant drop in blood pressure when a person stands up from sitting or lying down, leading to symptoms like dizziness, lightheadedness, or even fainting. This condition can be particularly prevalent in the elderly or in individuals with certain neurological disorders such as Parkinson’s disease. The treatment for orthostatic hypotension primarily aims to increase blood pressure and improve blood flow. Drugs commonly used for this condition include midodrine, which activates receptors on the smallest arteries and veins to increase vascular tone and blood pressure, and fludrocortisone, which enhances sodium retention to increase fluid volume in the circulatory system. Additionally, non-pharmacological strategies such as increased salt intake, wearing compression stockings, and physical maneuvers are often recommended alongside medication.

The development of drugs for orthostatic hypotension has been relatively moderate, focusing on symptomatic management rather than cure. However, recent advances in understanding the underlying pathophysiological mechanisms of the condition have opened up possibilities for targeted drug therapies. Researchers are exploring the roles of various neurotransmitters and hormonal pathways in regulating blood pressure and vascular tone. This has led to investigational therapies that aim to modulate these pathways more precisely, potentially offering more effective and sustainable treatment options. For example, novel agents that can enhance the responsiveness of the autonomic nervous system or improve cardiac output are under study. Additionally, there is growing interest in using combination therapies that address multiple mechanisms contributing to orthostatic hypotension, thus providing a more holistic approach to treatment.

The growth in the orthostatic hypotension drugs market is driven by several factors, including an aging global population, increased prevalence of diabetes and heart diseases, and improved diagnostic techniques that lead to higher detection rates of the condition. With the rise in elderly populations, who are more susceptible to orthostatic hypotension due to physiological changes and comorbid conditions, there is a corresponding increase in the demand for effective treatments. Furthermore, advancements in medical technologies and diagnostics are enabling better identification and understanding of various forms of blood pressure dysregulation, including orthostatic hypotension, leading to more targeted interventions. Consumer behavior also influences this market, as patients seek treatments that offer quick relief from symptoms and improve quality of life without significant side effects. The development of new drugs that can safely be combined with existing hypertension medications is also a critical area of research, driven by the need to manage orthostatic hypotension in patients with complex health profiles. Collectively, these drivers ensure ongoing investments and innovations in the development of orthostatic hypotension treatments.

Select Competitors (Total 86 Featured) -

  • Alembic Pharmaceuticals, Inc.
  • Avalo Therapeutics, Inc
  • Baxter International, Inc.
  • CuraSen Therapeutics
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Luye Pharma Group
  • Manus Aktteva Biopharma LLP
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Upsher-Smith Laboratories LLC
  • Viatris
  • Zydus Lifesciences Limited

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Orthostatic Hypotension Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Orthostatic Hypotension Drives Market Growth
    • Increasing Focus on Geriatric Healthcare Strengthens Business Case for Orthostatic Hypotension Drugs
    • Growing Awareness of Orthostatic Hypotension and Its Complications Expands Addressable Market Opportunity
    • Rising Demand for Alpha-Agonists and Mineralocorticoids Drives Market Dynamics
    • Increasing Adoption in Hospital and Ambulatory Care Settings Propels Market Growth
    • Expansion of Health Insurance Coverage Strengthens Market Adoption
    • Growing Trend of Home-Based and Long-Term Care Bodes Well for Market Expansion
    • Growth of the Aging Population Sets the Stage for Market Expansion
    • Increasing Use of Wearable Monitoring Devices Generates New Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Orthostatic Hypotension Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Orthostatic Hypotension Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Orthostatic Hypotension Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Midodrine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Midodrine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Midodrine Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Northera (Droxidopa) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Northera (Droxidopa) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Northera (Droxidopa) Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Fludrocortisone Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Fludrocortisone Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Fludrocortisone Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for ECG Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for ECG Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for ECG Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Blood Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Blood Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Stress Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Stress Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Stress Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Diagnostic Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Diagnostic Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Diagnostic Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • JAPAN
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • CHINA
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • EUROPE
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Orthostatic Hypotension Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Orthostatic Hypotension Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • FRANCE
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • GERMANY
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Orthostatic Hypotension Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Orthostatic Hypotension Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • INDIA
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Orthostatic Hypotension Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Orthostatic Hypotension Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Orthostatic Hypotension Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Orthostatic Hypotension Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030
  • AFRICA
    • Orthostatic Hypotension Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Orthostatic Hypotension Drugs by Drug Type - Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Orthostatic Hypotension Drugs by Drug Type - Percentage Breakdown of Value Sales for Midodrine Drug, Northera (Droxidopa) Drug, Fludrocortisone Drug and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Orthostatic Hypotension Drugs by Diagnostic Test - ECG Test, Blood Test, Stress Test and Other Diagnostic Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Orthostatic Hypotension Drugs by Diagnostic Test - Percentage Breakdown of Value Sales for ECG Test, Blood Test, Stress Test and Other Diagnostic Tests for the Years 2014, 2024 & 2030

IV. COMPETITION